tranexamic acid oral / Generic mfg. - LARVOL DELTA

Repetitive pulmonary embolism with local innate immune activation induces chronic thromboembolic pulmonary disease: A translational porcine study. (PubMed, Thromb Res) - "In this porcine model, repetitive PE combined with local cGAMP exposure increased lung tissue CXCL10 without inducing pulmonary hypertension over 30 days, suggesting that selective activation of the immune system at clot level alone is insufficient to drive a more advanced chronic thromboembolic phenotype."

Journal • Preclinical • Cardiovascular • Hematological Disorders • Hypertension • Inflammation • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • CXCL10 • CXCL8 • IL1B • TNFA

Balancing Bleeding and Ablation: Refractory HHT-Related Small Bowel Bleeding Despite Multimodal Therapy (ACG 2026) - "Management includes iron replacement, transfusion support, endoscopic ablation, antifibrinolytics for mild disease, and systemic anti-angiogenic therapy like bevacizumab for moderate-to-severe disease, with pazopanib emerging as an option...Tranexamic acid and intramuscular octreotide had not provided adequate symptom control...Double-balloon enteroscopy demonstrating numerous small bowel telangiectasias in the duodenum (AâB) and proximal jejunum (CâD). Approximately 30 lesions were identified, predominantly in the proximal jejunum, and treated with argon plasma coagulation."

Gastroenterology • Hematological Disorders

Effect of Aspirin Co-administration Under Tranexamic Acid Therapy on Postoperative Venous Thromboembolism After Total Knee Arthroplasty: A Prospective Double-blind Randomized Controlled Trial Using Lower Limb Ultrasonography (clinicaltrials.gov) - P=N/A | N=110 | Recruiting | Sponsor: Takagi Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Immunology • Orthopedics • Osteoarthritis • Rheumatology • Venous Thromboembolism

Efficacy and safety of tranexamic acid in non-gynecological abdominal and pelvic oncological surgery: a systematic review and meta-analysis. (PubMed, Thromb Res) - "Among patients undergoing non-gynecological abdominal and pelvic oncologic surgeries, TXA was not associated with a statistically significant reduction in perioperative transfusion rates or other clinically relevant outcomes, although a potential reduction in intraoperative blood loss was observed. Meanwhile, no statistically significant difference was observed in the risk of VTE and mortality."

Journal • Retrospective data • Review • Cardiovascular • Venous Thromboembolism

Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery (clinicaltrials.gov) - P1 | N=80 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: May 2026 ➔ May 2028 | Trial primary completion date: May 2026 ➔ May 2028

Trial completion date • Trial primary completion date • Oncology

Medication Regimens for Orthognathic Surgery: Comparative Effects on Hemodynamics and Pain Control. (PubMed, J Craniofac Surg) - "Standardized emergence-based anesthetic protocols were associated with improved early postoperative hemodynamic control and reduced acute pain after orthognathic surgery. TXA may independently reduce intraoperative MAP, although prospective studies are needed to validate these findings."

Journal • Anesthesia • Obstructive Sleep Apnea • Orthopedics • Pain • Respiratory Diseases • Sleep Disorder

Effect of Tranexamic Acid-Modified Leukocyte- and Platelet-Rich Fibrin on Hemostasis and Wound Healing After Tooth Extraction in Patients Receiving Direct Oral Anticoagulants (clinicaltrials.gov) - P=N/A | N=21 | Completed | Sponsor: Cumhuriyet University

New trial

Adding Tranexamic Acid to Hyaluronic Acid Improves Outcomes in Knee Osteoarthritis: Results from a Randomized Multicenter Trial (ACR Convergence 2026) - No abstract available

Clinical • Immunology • Osteoarthritis • Rheumatology

Efficacy and Safety of Various Medications in the Treatment of Hereditary Hemorrhagic Telangiectasia Epistaxis. (PubMed, Otolaryngol Head Neck Surg) - "No pharmacologic agent demonstrated consistent, clinically robust superiority over placebo across primary endpoints. Bevacizumab may modestly reduce bleeding burden, whereas tranexamic acid increases gastrointestinal toxicity without clear efficacy. Pharmacologic control of HHT-related epistaxis remains suboptimal, underscoring the need for adequately powered trials with standardized outcome measures and optimized dosing and delivery strategies."

Journal • Review • Hematological Disorders

Posterior spinal fusion for adolescent idiopathic scoliosis in a Jehovah's Witness. (PubMed, BMJ Case Rep) - "A structured multimodal blood-conservation protocol comprising tranexamic acid, controlled hypotensive anaesthesia, meticulous haemostasis and intra-operative cell salvage enabled safe completion of a 5-6-hour procedure without transfusion. This case adds to the limited literature describing scoliosis correction in Jehovah's Witness patients and highlights the ethical, surgical and perioperative considerations necessary to achieve a successful outcome in this complex setting."

Journal • Anesthesia • Orthopedics

Role of Tranexamic Acid in Reducing Transfusion Requirement in Calvarial Vault Remodeling (ACS-CLINCON 2026) - "Abstract is embargoed at this time."

Intraoperative Tranexamic Acid Is Associated with Reduced Length of Stay in Geriatric Hip Fracture Patients: A Single-Center Retrospective Cohort Study (ACS-CLINCON 2026) - "Abstract is embargoed at this time."

Retrospective data • Musculoskeletal Diseases • Orthopedics

Sterility of Tranexamic Acid Syringes Prefilled by Tactical Combat Medics in a Garrison Setting. (PubMed, J Spec Oper Med) - "Present findings suggest that TXA syringes prepared in a simulated operational environment can maintain sterility up to 6 days when stored at room temperature. These results directly inform the Committee on Tactical Combat Casualty Care (CoTCCC) regarding the safe storage duration of prefilled TXA syringes."

Journal • Hematological Disorders • Mood Disorders

Beyond conventional immunosuppression: tailoring perioperative management protocols for clinical xenotransplantation. (PubMed, Clin Transplant Res) - "The proposed framework encompasses immunologic assessment; porcine cytomegalovirus (PCMV)/roseolovirus-free donor certification; intensified induction; third-generation anti-CD154 monoclonal antibodies with pharmacokinetically verified trough targets; normothermic machine perfusion with anti-inflammatory perfusate supplementation; and thromboregulatory rescue protocols incorporating tranexamic acid, heparin, and antiplatelet agents. Furthermore, we aimed to address consumptive coagulopathy; targeted suppression of macrophage- and neutrophil-driven innate inflammatory cascades, alongside activation of xenoreactive natural killer cells; and multimodal surveillance integrating flow cytometry, donor-derived cell-free DNA, and metagenomic sequencing for porcine endogenous retrovirus and PCMV monitoring. By combining compassionate-use failure analysis with prospective trial design aligned with the 2026 International Society for Heart and Lung Transplantation consensus..."

Journal • Review • Antibody-mediated Rejection • Cytomegalovirus Infection • Hematological Disorders • Transplantation • CD40LG

HUB 1.10: Rethinking Hyperpigmentation Management: An Exclusive Tranexamic Acid Formulation (EADV 2026) - "This session is sponsored by: ACM Laboratoire Dermatologique"

Oral Tranexamic Acid Pretreatment Before Repeat Intense Pulsed Light in IPL-Refractory Erythematotelangiectatic Rosacea With VISIA-Detected Pigment Signal: A Retrospective Cohort Study. (EADV 2026) - No abstract available

Retrospective data • Dermatology • Rosacea

Oral Tranexamic Acid for Facial Hyperpigmentation in Frontal Fibrosing Alopecia: A Case Report (EADV 2026) - No abstract available

Case report • Clinical • Alopecia • Fibrosis • Immunology

Synergistic Depigmenting Efficacy and Superior Cutaneous Tolerability of Topical 20% Azelaic Acid Combined with 3% Tranexamic Acid in a Solar-Simulated Hyperpigmentation Model (EADV 2026) - No abstract available

Clinical

fficacy and Safety of a Novel Topical Formulation Combining 15% Azelaic Acid and 2% Tranexamic Acid in the Treatment of Acne-Induced Post-Inflammatory Hyperpigmentation (EADV 2026) - No abstract available

Clinical • Acne Vulgaris

Comparison of Efficacy and Safety of Intralesional Tranexamic Acid Versus Oral Tranexamic Acid Combined with 2% Hydroquinone in Melasma: A Randomised Prospective Interventional Study (EADV 2026) - No abstract available

Clinical • Dermatology • Dermatopathology

Hydroxy acid complex enhances topical skin delivery of tranexamic acid (EADV 2026) - No abstract available

Clinical Benefits of a Dermocosmetic Routine Containing 2-MNG, Tranexamic Acid, Niacinamide, and Retinol for Photoaged Facial Skin (EADV 2026) - No abstract available

Clinical

Understanding Skin Senescence (EADV 2026) - "Particular attention is paid to developments over the past year: the well-documented move away from hydroquinone monotherapy toward combination depigmenting regimens including thiamidol and tranexamic acid; refinements in peel formulation and priming; and the emerging — but still maturing — role of regenerative topicals and polynucleotide-based adjuncts, presented as promising rather than settled.Key Learning Objectives:Apply evidence-based, low-cost non-EBD techniques across diverse skin types and Fitzpatrick phototypes.Integrate the past year's key updates, particularly combination depigmenting regimens, while appraising which emerging adjuncts are evidence-backed and which remain investigational.Distinguish interventions supported by published evidence from those grounded in expert experience, enabling sound decisions in resource-conscious settings. The session celebrates the enduring value of clinical craft over capital expenditure — proof that thoughtful,..."

Aesthetic Medicine • Dermatopathology

My favourite non-EBD (EADV 2026) - "Temporary microchannels enhance penetration of active agents including tranexamic acid, peptides, growth factors and hair restoration formulations...In this lecture, I will discuss : The scientific basis of microneedlingRecent advancesCombination treatments with microneedlingPractical clinical pearls with special emphasis on acne scars, scar revision, rejuvenation and enlarged pores. Evolving combination strategies, regenerative applications Safety in skin of colour"

Acne Vulgaris • Aesthetic Medicine • Dermatology

Management of melasma in skin of colour (EADV 2026) - "To formulate stepwise treatment plans that integrate induction, transition and maintenance phases tailored to darker phototypes.To compare established and emerging topical and systemic therapies (including tranexamic acid) with specific attention to safety in skin of colour. To select and sequence procedural options—chemical peels, microneedling and energy‑based devices—using SOC‑appropriate parameters to minimise PIH.To apply long‑term counselling strategies that address chronicity, photoprotection, barrier repair and psychosocial impact in patients with melasma in skin of colour."

Aesthetic Medicine • Dermatology • Dermatopathology